Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan 15;209(2):225-226.
doi: 10.1164/rccm.202309-1605LE.

Still Thirsty in COPD!

Armeen D Poor  1
Affiliations
Comment

Still Thirsty in COPD!

Armeen D Poor. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply to Gan et al., to Calzetta et al., and to Poor.
    Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Anzueto A, et al. Am J Respir Crit Care Med. 2024 Jan 15;209(2):226-228. doi: 10.1164/rccm.202309-1657LE. Am J Respir Crit Care Med. 2024. PMID: 37939377 Free PMC article. No abstract available.

Comment on

References

    1. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet . 2022;399:2227–2242. - PubMed
    1. Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE Trials) Am J Respir Crit Care Med . 2023;208:406–416. - PMC - PubMed
    1. Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med . 2020;201:e56–e69. - PMC - PubMed
    1. Venkatesan P. GOLD COPD report: 2023 update. Lancet Respir Med . 2023;11:18. - PubMed
    1. Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. BOREAS Investigators Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med . 2023;389:205–214. - PubMed